{
    "doi": "https://doi.org/10.1182/blood.V118.21.3197.3197",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1931",
    "start_url_page_num": 1931,
    "is_scraped": "1",
    "article_title": "Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure Thalassemia Major Population, ",
    "article_date": "November 18, 2011",
    "session_type": "112. Thalassemia and Globin Gene Regulation: Poster III",
    "topics": [
        "cooley's anemia",
        "echocardiography",
        "heart failure",
        "left ventricular ejection fraction",
        "cardiac arrhythmia",
        "brachial plexus neuritis",
        "blood transfusion",
        "cardiac function, impaired",
        "diagnostic imaging",
        "ferritin"
    ],
    "author_names": [
        "Vitrano Angela, PhD",
        "Rita Barone, M.D.",
        "Gaetano Restivo Pantalone, M.D.",
        "Paolo Rigano, M.D.",
        "Marcello Capra, M.D.",
        "Liana Cuccia, M.D.",
        "Francesco Gagiardotto, M.D.",
        "Lorella Pitrolo, M.D.",
        "Luciano Prossomariti, M.D.",
        "Aldo Filosa, M.D.",
        "Maria Antonietta Romeo, M.D.",
        "Vincenzo Caruso, M.D.",
        "Crocetta Argento, M.D.",
        "Calogera Gerardi, M.D.",
        "Saveria Campisi, M.D.",
        "Pietro Violi, M.D.",
        "Paolo Cianciulli, M.D.",
        "Michele Rizzo, M.D.",
        "Giuseppe D'Ascola, M.D.",
        "Alessandra Quota, M.D.",
        "Carmelo Fidone, M.D.",
        "Gaetano Roccamo, M.D.",
        "Antonella Carollo, M.D.",
        "Luciana Rigoli, M.D.",
        "Francesca Valeria Commendatore, M.D.",
        "Roberto Giugno, M.D.",
        "Grazia Colletta, M.D.",
        "Rocca Cingari, M.D.",
        "Maria Concetta Galati, M.D.",
        "Antonella Quarta, M.D.",
        "Aurelio Maggio, M.D."
    ],
    "author_affiliations": [
        [
            "Dipartimento di Scienze Statistiche e Matematiche \u2018S. Vianelli', Universita\u0300 di Palermo, Italy, Palermo, Italy, "
        ],
        [
            "Hematology and Oncology, AO Villa Sofia-V. Cervello, Palermo, Italy, "
        ],
        [
            "Hematology and Oncology, AO Villa Sofia-V. Cervello, Palermo, Italy, "
        ],
        [
            "Hematology and Oncology, Ospedali Riuniti Villa Sofia- Cervello, Palermo, Italy, "
        ],
        [
            "Serv. Prevenz. Diagnosi e Cura Talassemia, Ospedale \u201cG. di Cristina\u201d, Palermo, Italy, "
        ],
        [
            "P.O.Ospedale Civico e Benfratelli, Palermo, Italia, "
        ],
        [
            "P.O.Ospedale Civico e Benfratelli, Palermo, Italia, "
        ],
        [
            "U.O.C. di Pediatria, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Vincenzo Cervello, Palermo, Italia, "
        ],
        [
            "Centro Regionale per la Cura delle Microcitemie, Azienda Ospedaliera Cardarelli, Napoli, Italia, "
        ],
        [
            "Unita\u0300 Operativa Complessa Pediatria, Azienda Ospedaliera Cardarelli, Napoli, Italia, "
        ],
        [
            "Dipartimento Pediatria, Azienda Policlinico, Catania, Italy, "
        ],
        [
            "Unita\u0300 Operativa Dipartimentale Talassemia, P.O. \u201cS. Luigi-Curro\u0300\u201d - ARNAS Garibaldi, Catania, Italy, "
        ],
        [
            "Unita\u0300 Operativa Complessa Medicina Trasfusionale, Azienda Ospedaliera San Giovanni di Dio, Agrigento, Italia, "
        ],
        [
            " P.O.\u201cGiovanni Paolo II\u201d Sciacca Distretto AG2 ASP Agrigento, Sciacca, Italy, "
        ],
        [
            "Unita\u0300 Operativa Semplice Centro Microcitemia, Azienda Ospedaliera Umberto I, Siracusa, Italia, "
        ],
        [
            "Centro della Microcitemia, San Giovanni Rotondo, Foggia, Italia, "
        ],
        [
            "Centro Talassemie, Ospedale \u201cSant'Eugenio Papa\u201d, Roma, Italy, "
        ],
        [
            "Rep. di Ematologia, Ospedale \u201cSant'Elia\u201d, Caltanisetta, Italy, "
        ],
        [
            "Centro Microcitemia, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italia, "
        ],
        [
            "Unita\u0300 Operativa Complessa Medicina Trasfusionale Azienda Ospedaliera Vittorio Emanuele III, Gela, Italia, "
        ],
        [
            "Unita\u0300 Operativa Complessa Centro Trasfusionale, Azienda Ospedaliera Maria Paterno\u0300 Arezzo, Ragusa, Italia, "
        ],
        [
            "Unita\u0300 di Prevenzione e Cura delle Mictrocitemie, Ospedale \u201cCivile\u201d, S. Agata di Militello (ME), Italy, "
        ],
        [
            "Servizio Talassemia-U.O. Pediatria Talassemia, Az. Osp. \u201cSant'Antonio abate\u201d, Trapani, "
        ],
        [
            "Policlinico \u201cG. Martino\u201d Dip. Scienze Pediatriche - U.O. Genetica ed Immunologia Pediatrica Messina,Italia, "
        ],
        [
            "ASL. 8 Siracusa Ospedale di Lentini-U.O. \u201cTalassemia\u201d Lentini,(Siracusa) Italia, "
        ],
        [
            "Azienda Ospedaliera \u201cGravina e Santo Pietro\u201dU.O. \u201cTalassemia\u201d Caltagirone, Italia, "
        ],
        [
            "P.O. \u201cS. Bambino\u201d U.O. Servizio di Talassemia,Catania,Italia, "
        ],
        [
            "A.O. Ferrarotto U.O. Ematologia,Catania,Italia, "
        ],
        [
            "Ospedale Civile Pugliese, Catanzaro.Italia, "
        ],
        [
            "Ematologia, Osp. \u201cA. Perrino\u201d, "
        ],
        [
            "UOC Ematologia II, Ospedali Riuniti \u201cVilla Sofia-Cervello\u201d, Palermo, Italy, Palermo, Italy"
        ]
    ],
    "first_author_latitude": "38.1177261",
    "first_author_longitude": "13.369923100000001",
    "abstract_text": "Abstract 3197 Background: The prognosis for thalassemia major (TM) has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop secondary iron overloading, and eventually death, particularly from cardiac disease. The possibility of detecting easily and earliest the patients at risk of cardiac death is so far the main challenge of clinical management of these patients. Therefore, the mean reduction of Left Ventricular Ejection Fraction (LVEF), determined by echocardiography, was evaluated over the time. Methods: Among the 413 observed patients only 188 had complete records for LVEF measurements during, at least, five considered consecutive years. Included patients were divided into two cohorts: the not alive and the alive-group with 22 and 166 patients, respectively. Generalized Estimating Equations (GEE) model was used to show the reduction of the mean of LVEF (Hedeker & Gibbons, 2006). This approach was implemented in the 'xtgee' procedure of Stata 11 software (StataCorp, College Station, TX, USA). The logistic regression model was used to evaluate the risk of death (Collet D. 2003). In this analysis, the mean reduction of LVEF was categorized into three levels: the baseline category including all patients with an increase greater than 0%, the category 1 including all patients with a reduction greater than 0% but less than 7% and the category 2 including all patients with a reduction higher or equal to 7%. All of the statistical analyses were performed under code at the Department for Mathematical and Statistical Sciences 'S. Vianelli', University of Palermo (Italy) by A.V. Results: Baseline findings are shown on Table I . Figure 1 shows the pro\u00deles of the GEE model for the mean LVEF between the two groups. The regression coefficient of Status\u00d7Time shows a statistically significant linear decrease over the time of 1,51 per year of the mean LVEF between not alive versus alive patients (Coeff. \u22121.51, CI (\u22122,31;\u22120,71), p-value<0,0001, Fig. 1 ). Patients with a mean reduction of LVEF greater or equal to 7% over the time had a statistical significant higher risk of death from heart failure (OR= 4,93,95% CI 1,61;15,11, p-value = 0,005). Table 1. Baseline findings among the 188 patients included in the study.  Findings . Not alive-group . Alive-group . p-value . N\u00b0 pts (188)  22 166  Females (%)  11 (50,00) 85 (51,21)  Treatment  1pt Sequential DFO-DFP, 21 pts DFO 84pts DFO, 47pts DFP, 35 Sequential DFO-DFP  Age in years  29 \u00b1 7,52 32 \u00b1 8,66 0,11 Hgb, g/l*  9,87 \u00b1 0,55 9,08 \u00b1 0,81 0,0005 ALT, IU/L*  71,37 \u00b1 36,52 48,51 \u00b1 39,33 0,0438 LIC, mg/g/dw  7272,5 \u00b1 11107,74 3014,58 \u00b1 3257,67 0,0329 Total blood transfusion, ml/kg/year  9007,18 \u00b1 2169,16 8829,55 \u00b1 2471,06 0,782 Mean ferritin, m g/l  2413,5 \u00b1 1497,12 1505,95 \u00b1 785,53 <0,0001 Mean basal EF < 55% (n\u00b0)  46,78 \u00b1 7,32 (9) 47,52 \u00b1 8,74 (19) 0,945 Basal mean ejection fraction  54,69 \u00b1 1,92 61,84 \u00b1 0.65 0,0003 Mean age at DFO starting, years  8,68 \u00b1 1,14 5,54 \u00b1 0,41 0,017 Splenectomy (%)  16 (72,72) 72 (43,37) 0,0336 Cirrhosis (%)  8 (36,36) 9 (5,42) 0,11 Arrhythmia (%)  10 (45,45) 23 (13,85) 0,0489 HCV-RNA positive (%)  15 (68,18) 47 (28,31) 0,0056 Findings . Not alive-group . Alive-group . p-value . N\u00b0 pts (188)  22 166  Females (%)  11 (50,00) 85 (51,21)  Treatment  1pt Sequential DFO-DFP, 21 pts DFO 84pts DFO, 47pts DFP, 35 Sequential DFO-DFP  Age in years  29 \u00b1 7,52 32 \u00b1 8,66 0,11 Hgb, g/l*  9,87 \u00b1 0,55 9,08 \u00b1 0,81 0,0005 ALT, IU/L*  71,37 \u00b1 36,52 48,51 \u00b1 39,33 0,0438 LIC, mg/g/dw  7272,5 \u00b1 11107,74 3014,58 \u00b1 3257,67 0,0329 Total blood transfusion, ml/kg/year  9007,18 \u00b1 2169,16 8829,55 \u00b1 2471,06 0,782 Mean ferritin, m g/l  2413,5 \u00b1 1497,12 1505,95 \u00b1 785,53 <0,0001 Mean basal EF < 55% (n\u00b0)  46,78 \u00b1 7,32 (9) 47,52 \u00b1 8,74 (19) 0,945 Basal mean ejection fraction  54,69 \u00b1 1,92 61,84 \u00b1 0.65 0,0003 Mean age at DFO starting, years  8,68 \u00b1 1,14 5,54 \u00b1 0,41 0,017 Splenectomy (%)  16 (72,72) 72 (43,37) 0,0336 Cirrhosis (%)  8 (36,36) 9 (5,42) 0,11 Arrhythmia (%)  10 (45,45) 23 (13,85) 0,0489 HCV-RNA positive (%)  15 (68,18) 47 (28,31) 0,0056 View Large Figure 1. View large Download slide Estimated profiles from the \u00detted GEE model for the two patient-groups: the not alive versus the alive-group. Figure 1. View large Download slide Estimated profiles from the \u00detted GEE model for the two patient-groups: the not alive versus the alive-group.  Discussion: Recently, Kirk et al. 2009 suggested as cardiac T2* magnetic resonance is able to detect patients at high risk of heart failure and arrhythmia from myocardial siderosis. However, other studies showed the presence of patients with abnormal heart function and normal heart T2* and did not suggest lower heart T2* for patients suffering from arrhythmia (Pepe et al., 2006; Marsella et al.,2011). Moreover, although the use of T2* is spreading, its availability is so far limited. Instead, availability of echocardiography is surely greater. Moreover, interobserver and intraobserver reliability for the visual assessment of the global LVEF measurements have been extensively shown even in comparison with Magnetic Resonace Imaging (Hoffmann et al. 2005; Gimelli et al. 2008; Blondheim et al., 2008; Sjzli et al. 2011). Therefore, repeated measurements of LVEF may be a strong and more accessible tool for detecting at risk of heart failure TM population. Disclosures: No relevant conflicts of interest to declare."
}